M K Bowling

742 total citations
10 papers, 604 citations indexed

About

M K Bowling is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, M K Bowling has authored 10 papers receiving a total of 604 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Oncology and 3 papers in Neurology. Recurrent topics in M K Bowling's work include Cancer therapeutics and mechanisms (6 papers), Cancer Treatment and Pharmacology (4 papers) and Neuroblastoma Research and Treatments (3 papers). M K Bowling is often cited by papers focused on Cancer therapeutics and mechanisms (6 papers), Cancer Treatment and Pharmacology (4 papers) and Neuroblastoma Research and Treatments (3 papers). M K Bowling collaborates with scholars based in United States. M K Bowling's co-authors include Ross C. Donehower, L B Grochow, Michael A. Carducci, Yelena Zabelina, Jeremy L. Gilbert, Sharyn D. Baker, Eric K. Rowinsky, Scott H. Kaufmann, S E Sartorius and William D. Figg and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology and PubMed.

In The Last Decade

M K Bowling

10 papers receiving 588 citations

Peers

M K Bowling

MB

ONCOL

PRM

RM

SURGE

Li‐En Shao United States

Scott R. Silva United States

S. M. LUDEMAN United States

Andrea Manni United States

Alexander Hermani Germany

A.-E. Roske Germany

Sabine Kajita Japan

Fan Fong Poon Hong Kong

Marcela Mrhalová Czechia

Li‐En Shao United States

M K Bowling

635 ×1.4

MB

150 ×0.6

ONCOL

31 ×0.6

PRM

28 ×0.6

RM

38 ×0.8

SURGE

Citations per year, relative to M K Bowling M K Bowling (= 1×) peers Li‐En Shao

Countries citing papers authored by M K Bowling

Since Specialization

Citations

This map shows the geographic impact of M K Bowling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M K Bowling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M K Bowling more than expected).

Fields of papers citing papers by M K Bowling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M K Bowling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M K Bowling. The network helps show where M K Bowling may publish in the future.

Co-authorship network of co-authors of M K Bowling

This figure shows the co-authorship network connecting the top 25 collaborators of M K Bowling. A scholar is included among the top collaborators of M K Bowling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M K Bowling. M K Bowling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Gilbert, Jeremy L., Sharyn D. Baker, M K Bowling, et al.. (2001). A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.. PubMed. 7(8). 2292–300. 172 indexed citations

2.

Wolff, Antonio C., et al.. (2001). A phase I study of diethylnorspermine (DENSPM) in previously treated patients with metastatic breast cancer (MBC). 69(3). 2 indexed citations

3.

Carducci, Michael A., Jeremy L. Gilbert, M K Bowling, et al.. (2001). A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.. PubMed. 7(10). 3047–55. 166 indexed citations

4.

Rowinsky, Eric K., D A Noe, L B Grochow, et al.. (1997). Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.. PubMed. 3(3). 401–7. 15 indexed citations

5.

Rowinsky, Eric K., L B Grochow, S E Sartorius, et al.. (1996). Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.. Journal of Clinical Oncology. 14(4). 1224–1235. 41 indexed citations

6.

Rowinsky, Eric K., Scott H. Kaufmann, Sharyn D. Baker, et al.. (1996). Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.. Journal of Clinical Oncology. 14(12). 3074–3084. 122 indexed citations

7.

Rowinsky, Eric K., Scott H. Kaufmann, Sharyn D. Baker, et al.. (1996). A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.. PubMed. 2(12). 1921–30. 35 indexed citations

8.

Rowinsky, Eric K., D A Noe, L B Grochow, et al.. (1995). Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules.. Journal of Clinical Oncology. 13(8). 1975–1984. 33 indexed citations

9.

Slichenmyer, William J., et al.. (1995). Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia.. PubMed. 36(3). 227–32. 10 indexed citations

10.

Donehower, Ross C., et al.. (1995). Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia. Cancer Chemotherapy and Pharmacology. 36(3). 227–232. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact